Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 4, 1998, Pages 735-740

  Eulau, Stephen M ^a   Tate, David J ^a   Stamey, Thomas A ^a   Bagshaw, Malcolm A ^a   Hancock, Steven L ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Androgen deprivation; Hormonal therapy; Postoperative radiotherapy; Prostatic neoplasms

Indexed keywords

ANDROGEN RECEPTOR; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 0031804260     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00127-8     Document Type: Article

References (34)

1. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (Stage T2c or lower) prostate cancer. J. Urol. 152:1994;1850-1857.
2. Walsh P.C., Partin A.W., Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy Results at 10 years . J. Urol. 152:1994;1831-1836.
3. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol. 149:1993;516-518.
4. Anscher M.S., Prosnitz L.R. Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy. Int. J. Rad. Oncol. Biol. Phys. 21:1991;941-947.
5. Anscher M.S., Robertson C.N., Prosnitz L.R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate 10 year update . Int. J. Radiat. Oncol. Biol. Phys. 33:1995;37-43.
6. Gibbons R.P., Cole B.S., Richardson R.G., et al. Adjuvant radiotherapy following radical prostatectomy Results and complications . J. Urol. 135:1986;65-68.
7. Kaplan I.D., Bagshaw M.A. Serum prostate specific antigen after post-prostatectomy radiotherapy. Urology. 39:1992;401-406.
8. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141:1989;873-879.
9. Meier R., Mark R., St. Royal L., et al. Postoperative radiation therapy after radical prostatectomy for prostate carcinoma. Cancer. 70:1992;1960-1966.
10. Stamey T.A., Graves H.C., Wehner N., et al. Early detection of residual prostate cancer after radical prostatectomy by ultrasensitive assay for prostate specific antigen. J. Urol. 149:1993;787-792.
11. Gehan E.A. A generalized Wilcoxan test for arbitrarily singly-censored samples. Biometrika. 52:1965;203-233.
12. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:1957;457-481.
13. Catalona W.J., Stein A.J. Staging errors in clinically localized prostatic cancer. J. Urol. 127:1982;452-456.
14. Lange P.H., Narayan P. Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant therapy. Urology. 21:1983;113-116.
15. Lange P.H., Moon T.D., Narayan P. Radiation therapy as adjuvant treatment after radical prostatectomy Patient tolerance and preliminary results . J. Urol. 136:1986;45-49.
16. Forman J.D., Wharam M.D., Lee D.J., et al. Definitive radiotherapy following prostatectomy Results and complications . Int. J. Radiat. Oncol. Biol. Phys. 12:1986;185-189.
17. Zietman A.L., Coen J.J., Shipley W.U., et al. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate Analysis of freedom from PSA failure . Urology. 42:1993;292-298.
18. Huggins C., Hodges C.V. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic cancer of the prostate . Cancer Res. 1:1941;293-297.
19. English H.F., Kyprianou N., Isaacs J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate. 15:1989;233-289.
20. Meyn R.E., Stephens L.C., Ang K.K., et al. Heterogeneity in the development of apoptosis in irradiated murine tumors of different histologies. Int. J. Radiat. Oncol. Biol. Phys. 64:1993;583-591.
21. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337:1997;295-300.
22. Pilepich M.V., Sause W.T., Shipley W.U., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
23. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321:1989;419-424.
24. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of the human prostate specific antigen. Invest. Urol. 17:1979;159-165.
25. Murphy W.M., Soloway M.S., Barrows G.H., et al. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 68:1991;821-828.
26. Young C.Y.F., Montgomery B.T., Andrew P.E., et al. Hormonal regulation of prostate specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 51:1991;3748-3752.
27. Buskirk S.J., Schild S.E., Durr E.D., et al. Evaluation of serum PSA levels after postoperative radiation therapy for pathologic stage T3, NO prostate cancer. Mayo Clin. Proc. 71:1996;242-248.
28. McCarthy J.F., Catalona W.J., Hudson M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy Early versus delayed treatment . J. Urol. 151:1994;1575-1578.
29. Yamada A.H., Lieskovsky G., Petrovich Z., et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced clinical stage C prostate cancer. Am. J. Clin. Oncol. 17:1994;277-285.
30. Stein A., deKernion J.B., Smith R.B., et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol. 147:1992;942-946.
31. Link P., Freiha F.S., Stamey T.A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J. Urol. 145:1991;532-534.
32. Schild S.E., Wong W.W., Grado G.L., et al. Radiotherapy for isolated increases in serum prostate specific antigen levels after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;535-541.
33. Petrovich Z., Lieskovsky G., Langholz B., et al. Radical prostatectomy and postoperative irradiation in patients with pathological Stage C (T3) carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;139-147.
34. Forman J.D., Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology. 12:1998;33-39.